OBJECTIVE: To investigate the spontaneous occurrence of circulating mesenchymal stem cells (MSC) and angiogenic factors in patients with ST elevation acute myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI). DESIGN: In 20 patients with STEMI, blood samples were obtained on days 1, 3, 7, 14, 21, and 28 after the acute PCI. Fifteen patients with a normal coronary angiography formed a control group. MSC (CD45-/CD34-), plasma stromal derived factor 1 (SDF-1), vascular endothelial growth factor A (VEGF-A), and fibroblast growth factor 2 (FGF-2) were measured by multiparametric flow cytometry and enzyme linked immunosorbent assay (ELISA). RESULTS: Circulating CD45-/CD34- cells were significantly decreased on day 7 compared with day 3. Cell counts normalised one month after the acute onset of STEMI. The changes were mainly seen in patients with a large infarction. Plasma SDF-1 increased significantly from day 3 to day 28, and VEGF-A and FGF-2 increased significantly from day 7 to day 28. CONCLUSIONS: Spontaneous sequential fluctuations in MSC and the increase in vascular growth factor concentrations after STEMI suggest that the optimal time for additional stem cell therapy is three weeks after a myocardial infarction to obtain the maximum effects by stimulating endogenous growth factors on the delivered stem cells.
OBJECTIVE: To investigate the spontaneous occurrence of circulating mesenchymal stem cells (MSC) and angiogenic factors in patients with ST elevation acute myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI). DESIGN: In 20 patients with STEMI, blood samples were obtained on days 1, 3, 7, 14, 21, and 28 after the acute PCI. Fifteen patients with a normal coronary angiography formed a control group. MSC (CD45-/CD34-), plasma stromal derived factor 1 (SDF-1), vascular endothelial growth factor A (VEGF-A), and fibroblast growth factor 2 (FGF-2) were measured by multiparametric flow cytometry and enzyme linked immunosorbent assay (ELISA). RESULTS: Circulating CD45-/CD34- cells were significantly decreased on day 7 compared with day 3. Cell counts normalised one month after the acute onset of STEMI. The changes were mainly seen in patients with a large infarction. Plasma SDF-1 increased significantly from day 3 to day 28, and VEGF-A and FGF-2 increased significantly from day 7 to day 28. CONCLUSIONS: Spontaneous sequential fluctuations in MSC and the increase in vascular growth factor concentrations after STEMI suggest that the optimal time for additional stem cell therapy is three weeks after a myocardial infarction to obtain the maximum effects by stimulating endogenous growth factors on the delivered stem cells.
Authors: Kai C Wollert; Gerd P Meyer; Joachim Lotz; Stefanie Ringes-Lichtenberg; Peter Lippolt; Christiane Breidenbach; Stephanie Fichtner; Thomas Korte; Burkhard Hornig; Diethelm Messinger; Lubomir Arseniev; Bernd Hertenstein; Arnold Ganser; Helmut Drexler Journal: Lancet Date: 2004 Jul 10-16 Impact factor: 79.321
Authors: T Asahara; H Masuda; T Takahashi; C Kalka; C Pastore; M Silver; M Kearne; M Magner; J M Isner Journal: Circ Res Date: 1999-08-06 Impact factor: 17.367
Authors: Volker Schächinger; Birgit Assmus; Martina B Britten; Jörg Honold; Ralf Lehmann; Claudius Teupe; Nasreddin D Abolmaali; Thomas J Vogl; Wolf-Karsten Hofmann; Hans Martin; Stefanie Dimmeler; Andreas M Zeiher Journal: J Am Coll Cardiol Date: 2004-10-19 Impact factor: 24.094
Authors: A Kawamoto; H Kawata; Y Akai; Y Katsuyama; E Takase; Y Sasaki; S Tsujimura; Y Sakaguchi; M Iwano; S Fujimoto; T Hashimoto; K Dohi Journal: Int J Cardiol Date: 1998-11-30 Impact factor: 4.164
Authors: Arman T Askari; Samuel Unzek; Zoran B Popovic; Corey K Goldman; Farhad Forudi; Matthew Kiedrowski; Aleksandr Rovner; Stephen G Ellis; James D Thomas; Paul E DiCorleto; Eric J Topol; Marc S Penn Journal: Lancet Date: 2003-08-30 Impact factor: 79.321
Authors: Charles E Murry; Mark H Soonpaa; Hans Reinecke; Hidehiro Nakajima; Hisako O Nakajima; Michael Rubart; Kishore B S Pasumarthi; Jitka Ismail Virag; Stephen H Bartelmez; Veronica Poppa; Gillian Bradford; Joshua D Dowell; David A Williams; Loren J Field Journal: Nature Date: 2004-03-21 Impact factor: 49.962
Authors: Chrisoula A Toupadakis; Jennifer L Granick; Myrrh Sagy; Alice Wong; Ehssan Ghassemi; Dai-Jung Chung; Dori L Borjesson; Clare E Yellowley Journal: Cytotherapy Date: 2013-07-03 Impact factor: 5.414
Authors: Shaowei Li; Ke-Jung Huang; Jen-Chieh Wu; Michael S Hu; Mrinmoy Sanyal; Min Hu; Michael T Longaker; H Peter Lorenz Journal: Stem Cells Transl Med Date: 2015-03-05 Impact factor: 6.940
Authors: Tariq G Fellous; Andia N Redpath; Mackenzie M Fleischer; Sapan Gandhi; Samantha E Hartner; Michael D Newton; Moïra François; Suet-Ping Wong; Kate H C Gowers; Adam M Fahs; Daniel R Possley; Dominique Bonnet; Paula Urquhart; Anna Nicolaou; Kevin C Baker; Sara M Rankin Journal: NPJ Regen Med Date: 2020-02-21
Authors: Thomas J Povsic; Samer S Najjar; Kristi Prather; Jiying Zhou; Stacie D Adams; Katherine L Zavodni; Francine Kelly; Laura G Melton; Vic Hasselblad; John F Heitner; Subha V Raman; Gregory W Barsness; Manesh R Patel; Raymond J Kim; Edward G Lakatta; Robert A Harrington; Sunil V Rao Journal: J Thromb Thrombolysis Date: 2013-11 Impact factor: 2.300